180 related articles for article (PubMed ID: 32194900)
1. Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.
Chen Q; Xia R; Zheng W; Zhang L; Li P; Sun X; Shi J
Am J Transl Res; 2020; 12(2):519-530. PubMed ID: 32194900
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells.
Sanchez Y; Vasquez Callejas MA; Miret NV; Rolandelli G; Costas C; Randi AS; Español A
Explor Target Antitumor Ther; 2024; 5(2):278-295. PubMed ID: 38745771
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers.
Hsu MY; Hsieh CH; Huang YT; Chu SY; Chen CM; Lee WJ; Liu SJ
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283075
[TBL] [Abstract][Full Text] [Related]
5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
8. A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy.
Hu D; Zhang W; Xiang J; Li D; Chen Y; Yuan P; Shao S; Zhou Z; Shen Y; Tang J
Mater Today Bio; 2022 Mar; 14():100284. PubMed ID: 35647515
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
10. Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer.
Li X; Luo X; Hu S
Bioimpacts; 2023; 13(2):89-96. PubMed ID: 37193073
[No Abstract] [Full Text] [Related]
11. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
[TBL] [Abstract][Full Text] [Related]
12. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
13. Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC.
Vetrei C; Passariello M; Froechlich G; Rapuano Lembo R; Sasso E; Zambrano N; De Lorenzo C
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008285
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
17. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Zhang M; Chen C; Su F; Huang Z; Li X; Li X
Technol Cancer Res Treat; 2017 Oct; 16(5):609-619. PubMed ID: 27573201
[TBL] [Abstract][Full Text] [Related]
19. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
20. Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model.
Lu Y; Huang X; Liu X; He Y; Hu Z; Xu W; Cao G; He W
Onco Targets Ther; 2021; 14():2247-2258. PubMed ID: 33833524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]